Achaogen, Inc.
12
0
0
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
91.7%
+5.2% vs industry average
17%
2 trials in Phase 3/4
27%
3 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Role: lead
A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
Role: lead
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
Role: lead
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789
Role: lead
A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin
Role: lead
A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin
Role: lead
A Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers
Role: lead
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers
Role: lead
PK Study of ACHN-490 Injection in Renally Impaired Subjects
Role: lead
A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers
Role: lead
Phase 1 Study to Determine Safety, Blood PK and Lung Penetration
Role: lead
Phase 1 Study for Safety of ACHN-490
Role: lead
All 12 trials loaded